CA2321947A1 - Anticorps monoclonaux anti-ace humanises et faisant preuve d'une grande affinite - Google Patents

Anticorps monoclonaux anti-ace humanises et faisant preuve d'une grande affinite Download PDF

Info

Publication number
CA2321947A1
CA2321947A1 CA002321947A CA2321947A CA2321947A1 CA 2321947 A1 CA2321947 A1 CA 2321947A1 CA 002321947 A CA002321947 A CA 002321947A CA 2321947 A CA2321947 A CA 2321947A CA 2321947 A1 CA2321947 A1 CA 2321947A1
Authority
CA
Canada
Prior art keywords
humanized
ser
humanized antibody
thr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002321947A
Other languages
English (en)
Inventor
William Henry Kerr Anderson
Philip R. Tempest
Frank J. Carr
William J. Harris
Kathryn Armour
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dow Chemical Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2321947A1 publication Critical patent/CA2321947A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6853—Carcino-embryonic antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1048—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne de nouveaux anticorps monoclonaux humanisés ainsi que des fragments ou des dérivés de ces anticorps, lesquels se lient de manière spécifique à l'antigène carcino-embryonnaire (ACE). Cette invention concerne également des procédés de production des ces anticorps et de leurs fragments ou dérivés. Ces anticorps humanisés sont utiles dans le traitement des cancers qui expriment l'ACE, ainsi qu'à des fins diagnostiques comme, par exemple, l'imagerie in vivo de tumeurs ou de cellules cancéreuses qui expriment l'ACE.
CA002321947A 1998-02-25 1998-02-25 Anticorps monoclonaux anti-ace humanises et faisant preuve d'une grande affinite Abandoned CA2321947A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/003680 WO1999043817A1 (fr) 1998-02-25 1998-02-25 Anticorps monoclonaux anti-ace humanises et faisant preuve d'une grande affinite

Publications (1)

Publication Number Publication Date
CA2321947A1 true CA2321947A1 (fr) 1999-09-02

Family

ID=22266464

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002321947A Abandoned CA2321947A1 (fr) 1998-02-25 1998-02-25 Anticorps monoclonaux anti-ace humanises et faisant preuve d'une grande affinite

Country Status (7)

Country Link
EP (1) EP1056859A1 (fr)
JP (1) JP2002504372A (fr)
AU (1) AU752494B2 (fr)
CA (1) CA2321947A1 (fr)
IL (1) IL138022A0 (fr)
NO (1) NO20004251L (fr)
WO (1) WO1999043817A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003025565A2 (fr) * 2001-09-21 2003-03-27 Caprion Pharmaceuticals Inc. Preparation de membranes plasmiques fortement purifiees
CA2609142C (fr) 2005-05-27 2016-02-09 Fondazione Centro San Raffaele Del Monte Tabor Vecteurs geniques therapeutiques comprenant des sequences cibles de microarn
DK2681244T3 (da) * 2011-03-02 2018-01-29 Roche Glycart Ag Cea-antistoffer
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CN111533805B (zh) * 2016-12-04 2022-02-08 深圳市国创纳米抗体技术有限公司 一种抗癌胚抗原的高亲和力纳米抗体及其应用
CN113906053B (zh) 2019-06-26 2022-10-25 江苏恒瑞医药股份有限公司 抗cea抗体及其应用
CA3188862A1 (fr) 2020-08-20 2022-02-24 Carl Alexander Kamb Compositions et methodes de traitement de cancers positifs a la mesotheline
CN116724052A (zh) 2020-08-20 2023-09-08 A2生物治疗股份有限公司 用于治疗ceacam阳性癌症的组合物和方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5472693A (en) * 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
CA2250579A1 (fr) * 1996-05-04 1997-11-13 Zeneca Limited Anticorps monoclonal anti-cea, conjugues contenant cet anticorps et leur utilisation therapeutique dans un systeme adept

Also Published As

Publication number Publication date
NO20004251D0 (no) 2000-08-24
JP2002504372A (ja) 2002-02-12
NO20004251L (no) 2000-10-24
EP1056859A1 (fr) 2000-12-06
WO1999043817A1 (fr) 1999-09-02
IL138022A0 (en) 2001-10-31
AU752494B2 (en) 2002-09-19
AU6338898A (en) 1999-09-15

Similar Documents

Publication Publication Date Title
US6417337B1 (en) High affinity humanized anti-CEA monoclonal antibodies
JP3904238B2 (ja) グリコシル化されたヒト化ｂ細胞特異的抗体
US6676924B2 (en) CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
EP0771208B1 (fr) Immunoconjugues et anticorps de type humain specifiques contre des lymphomes malins a cellules b et des cellules leucemiques
JP4538062B2 (ja) 二重特異性抗体とともに使用される新規なペプチド型薬剤の製造および使用
US7951369B2 (en) Chimeric, human and humanized anti-granulocyte antibodies and methods of use
WO2005112564A2 (fr) Régions variables d'anticorps humanisés et lignée germinale et méthodes de fabrication et d'utilisation
US6753420B2 (en) High affinity humanized anti-Tag-72 monoclonal antibodies
US20090311780A1 (en) Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use
AU752494B2 (en) High affinity humanized ANTI-CEA monoclonal antibodies
EP1056860B1 (fr) Anticorps monoclonaux anti-tag-72 humanises et faisant preuve d'une grande affinite
US20030165498A1 (en) Composite antibodies of humanized human subgroup IV light chain capable of binding to TAG-72
MXPA00008391A (en) High affinity humanized anti-cea monoclonal antibodies
TW523521B (en) High affinity humanized anti-TAG-72 monoclonal antibodies
TW553949B (en) High affinity humanized anti-CEA monoclonal antibodies
MXPA00008390A (en) High affinity humanized anti-tag-72 monoclonal antibodies

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued